AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and preliminary
anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients
with EGFR mutation positive advanced lung cancer
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Antibodies, Monoclonal Coal Tar Durvalumab Osimertinib